Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001240292 | SCV001413223 | likely benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002491792 | SCV002804309 | likely benign | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2021-07-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002563972 | SCV003712204 | uncertain significance | Inborn genetic diseases | 2021-07-15 | criteria provided, single submitter | clinical testing | The c.6545G>A (p.R2182H) alteration is located in exon 35 (coding exon 34) of the CACNA1H gene. This alteration results from a G to A substitution at nucleotide position 6545, causing the arginine (R) at amino acid position 2182 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Athena Diagnostics | RCV004998763 | SCV005620721 | uncertain significance | not provided | 2024-12-09 | criteria provided, single submitter | clinical testing |